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Abstract
Purpose—A meta-analysis was conducted to evaluate the inter-patient pharmacokinetic (PK)
variability of liposomal and small molecule (SM) anticancer agents.
Methods—Inter-patient PK variability of 9 liposomal and SM formulations of the same drug
were evaluated. PK variability was measured as coefficient of variance (CV%) of area under the
plasma concentration versus time curve (AUC) and the fold-difference between AUCmax and
AUCmin (AUC range).
Results—CV% of AUC and AUC ranges were 2.7-fold (P<0.001) and 16.7-fold (P=0.13)
greater, respectively, for liposomal compared with SM drugs. There was an inverse linear
relationship between the clearance (CL) of liposomal agents and PK variability with a lower CL
associated with greater PK variability (R2 = 0.39). PK variability of liposomal agents was greater
when evaluated from 0–336 h compared with 0–24 h.
Conclusion—PK variability of liposomes is significantly greater than SM. The factors
associated with the PK variability of liposomal agents needs to be evaluated.
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Most anticancer agents have high inter-patient variability in pharmacokinetic (PK)
disposition, with systemic exposure following standard doses varying as much as 10-fold
between patients [1–3]. This contributes in part to variability in a drug’s pharmacodynamic
(PD) effects, making it difficult to predict how a particular patient will respond in terms of
efficacy and/or toxicity [4]. The same dose of drug may result in a sub-therapeutic response
in one patient and unacceptable toxicity in another [5]. This problem is highlighted in
cytotoxic agents that often display a narrower therapeutic index compared with other drug
classes, such as statins and most antibiotics, where a wide range of doses may elicit the
desired response with few adverse effects. Thus, anticancer agents have a small range of
doses and exposures in which a drug is efficacious but not overly toxic [1]. Many factors
such as patient demographics (age, gender, and body surface area), genetics, and the
environment are known to alter the PK of a drug. Hence, these factors serve as potential
causes of the inter-patient PK and PD variability associated with anticancer agents [1, 6, 7].
Various strategies have been proposed to increase the therapeutic index of anticancer drugs
while minimizing side effects. One such approach is altering conventional drug delivery
systems through use of carrier vehicles to deliver active agents to the site of action [9].
Liposomes represent a promising carrier vehicle with the potential for targeting specific
organs or tissues [8]. Furthermore, delivering agents via liposomes has demonstrated
advantages over conventional chemotherapeutics including increased solubility of
hydrophobic agents, greater stability of large compounds, prolonged systemic drug
exposure, and potential for improved efficacy and reduced toxicity [9].
A liposome is a type of nanoparticle carrier, usually 50 to 200 nm in diameter, consisting of
an aqueous core surrounded by one or more phospholipid layers [10, 11]. Active drugs are
encapsulated in the liposome, with hydrophilic and lipophilic compounds entrapped in the
aqueous core and phospholipid bilayer, respectively [12]. While a drug is encapsulated in a
liposome, its PK disposition depends on the physiochemical properties of the carrier. An
encapsulated agent remains an inactive prodrug and therefore must be released from the
liposome to elicit its effects [13]. Once released, the PK disposition of the drug resembles
that of the active drug administered in the absence of a carrier [14, 15]. Thus, the PK of
liposomal encapsulated drug and released drug is very different. In addition, the PK
disposition of liposomal agents is significantly different than conventional anticancer agents.
Moreover, the PK variability of liposomal formulations appears to be much greater than
small molecule drugs. Inter-patient variability in drug exposure, represented by area under
the concentration-time curve (AUC), of encapsulated drug can be 20- to 100-fold [28].
However, some liposomal agents report relatively low PK variability [41].
The factors with the potential to affect liposomal PK include liposomal-associated
formulation characteristics (particle size, surface charge, lipid composition, ligand
conjugation) [8, 16–20] and host-associated characteristics (age, gender, body composition,
prior treatment) [21–24]. Additionally, dose schedule and drug-drug interactions may alter
drug response between patients. Perhaps the greatest influence on the PK variability of
liposomes; however, is the mononuclear phagocytic system (MPS) and its role in driving the
clearance of liposomes [45, 46]. The MPS is a family of cells comprised of bone marrow
precursors, blood monocytes, and tissue macrophages [25]. The MPS clears liposomes by its
capacity to engulf liposomes via their phagocytic function, which removes them from
circulation [26, 27].
While inter-patient variability in the PK disposition of a liposome is often higher than that of
a conventional formulation of the same drug, comprehensive differences in PK variability
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between liposomal agents compared with non-liposomal agents has not been systematically
evaluated. Therefore, we conducted a systematic review and meta-analysis investigating
AUC variability differences between liposomal and non-liposomal formulations of 9
anticancer agents.
Considering the large inter-patient PK variability and the inconsistent reports of PK
variability of some liposomal agents, we sought to determine how study design and
sampling schema might affect the documentation of PK variability. Due to prolonged
systemic exposure of encapsulated drug, PK studies of liposomes must extend sample
collection to include later time points (e.g. day 7 to 14) than those required with
conventional formulations with shorter half-lives in order to accurately calculate PK
parameters and fully characterize PK variability in patients. Thus, we hypothesized that
studies utilizing limited sampling schemas (e.g. 0 to 24 h) underestimate inter-patient PK
variability in drug exposure of liposomal agents. To test our hypothesis, we evaluated the
estimated PK variability of PEGylated liposomal CKD-602 (S-CKD602) and non-liposomal
CKD-602 (NL-CKD602) using data obtained from two separate phase I studies of patients
with advanced solid tumors. NL-CKD602 is currently approved in Korea under the trade
name Belotecan® for the treatment of newly diagnosed small-cell lung cancer and relapsed
ovarian cancer [21]. NL-CKD602 is administered at a dosage of 0.5 mg/m2/day IV for 5
consecutive days repeated every 21 days. S-CKD602 is a PEGylated liposomal formulation
of CKD-602 that has completed phase I studies. We compared differences in estimated
inter-patient PK variability when using a short (0–24 h) versus a long (0–336 h) sampling
schema for S-CKD602 and NL-CKD602.
Patients and Methods
Systematic Review and Meta-analysis
To directly compare interpatient PK variability of multiple liposomal and non-liposomal
anticancer agents, a systematic review and meta-analysis was conducted utilizing PubMed
(1966–2011) and manual searches of reference sections of key articles. Phase I and II studies
that included PK studies were included in our analysis. The systematic review yielded 9
liposomal and non-liposomal formulations of the same anticancer agents. A complete list of
evaluated agents with a brief description of each is listed in Table 1. The mean ± SD AUC
were collected for liposomal and non-liposomal formulations of each agent at similar doses.
Inter-patient variability in drug exposure was quantified using the coefficient of variation
(CV%). The ratio of CV% of AUC of the liposomal formulation to the non-liposomal
formulation of the same drug at similar doses was calculated using the following equation:
(Eq 1)
The maximum AUC (AUCmax) and minimum AUC (AUCmin) reported for each formulation
at similar doses were also collected. The ratio of AUCmax to AUCmin of the liposomal
formulation to the non-liposomal formulation of the same drug was also calculated using the
following equation:
(Eq 2)
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Influence of Drug Clearance on Interpatient PK Variability
To evaluate how a drug’s clearance rate may impact observed interpatient PK variability, we
calculated average total body clearance of each agent evaluated in the meta-analysis and
plotted these values against CV% of AUC values. This analysis was performed for both the
liposomal and non-liposomal formulations of each agent. Doses evaluated for each
liposomal formulation represent the MTD determined from published PK studies. The
closest corresponding non-liposomal doses available in the literature were used in the non-
liposomal analysis.
Impact of Sampling Schema on Reported Interpatient PK Variability
To investigate differences in the reported interpatient PK variability of a liposomal agent
when using a long versus short sampling schema, PK parameters for patients who were
given S-CKD602 as part of a phase I study in patients with refractory solid tumors were
calculated using a non-compartmental analysis in WinNonlin 5.2 software (Pharsight,
Mountain View, California). Written informed consent, approved by the Institutional
Review board of the University of Pittsburgh Medical Center, was obtained from all patients
prior to entry into the original phase I study. Based on published PK study designs used in
liposomal and non-liposomal studies in patients and logistical issues with performing PK
studies after 24 h, we defined the short and long PK sampling schemas as 0 to 24 h and 0 to
336 h, respectively. The mean ± SD, and CV% of AUC was calculated for encapsulated
CKD-602 from 0 h to 24 h (AUC0–24) and from 0 h to 336 h (AUC0–336) at each dose level
in the S-CKD602 study. CV% of AUC0–24 and CV% of AUC0–336 were calculated for each
dose level. Furthermore, the ratio of CV% of AUC0–336 to CV% of AUC0–24 was calculated
for each dose level to assess the fold-difference in interpatient PK variability between a long
and short sampling schema using the following equation:
(Eq 3)
As another means of quantifying variability in S-CKD602 exposure, the maximum AUC
(AUCmax) and minimum AUC (AUCmin) were determined for each dose level. The ratio of
AUCmax to AUCmin of the long sampling schema to the short sampling schema was then
calculated for each dose level using the following equation:
(Eq 4)
Statistical Analysis
In the meta-analysis comparing PK variability between liposomal and non-liposomal
formulations of the same anticancer agent, paired t-tests were used to compare the ratios of
both CV% of AUC and AUCmax to AUCmin of the liposomal formulation to the non-
liposomal formulation of the same drug. A paired t-test was also used in the S-CKD602 PK
analysis to evaluate differences between estimated AUC values calculated using a short and
long sampling schema.
Results
Meta-analysis of PK Variability
We compared inter-patient PK variability differences of corresponding liposomal and non-
liposomal anticancer agents at similar doses. Figure 1 represents the plasma concentration
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versus time profiles of liposomal and non-liposomal CKD-602, one of the 9 agents
evaluated in the meta-analysis. Here, each agent was administered to 6 patients at the
respective MTD (S-CKD602 at 2.10 mg/m2 and NL-CKD602 at 0.5 mg/m2). Visual
inspection reveals a tighter grouping of profiles between patients administered NL-CKD602
compared to those receiving S-CKD602, demonstrating a reduction in PK variability
observed in a non-liposomal agent compared with that of a liposomal agent.
To further evaluate the degree of PK variability of liposomal and non-liposomal agents, a
meta-analysis was performed comparing the PK variability of liposomal and conventional
small molecule formulations of the same drug. CV% of AUC values for both liposomal (n =
9) and conventional (n = 9) formulations of each evaluated agent are depicted in Figure 2A.
Mean CV% of AUC values and mean ratio of AUCmax to AUCmin values are depicted in
Figure 2B. The PK variability of every liposomal agent was greater than the corresponding
non-liposomal agent (Figure 2A). The mean CV% and range of PK variability for liposomal
and non-liposomal agents were approximately 2.1-fold and 8.7-fold higher, respectively, for
liposomal compared with non-liposomal agents.
CV% of AUC, ratio of AUCmax to AUCmin values (mean ± SD), and corresponding ratios of
liposomal to non-liposomal agents are reported in Table 2. For liposomal agents, the mean ±
SD of CV% of AUC was 65.6 ± 18.6%. For non-liposomal agents, the mean ± SD of CV%
of AUC was 30.7 ± 16.0%. The ratio of liposomal to non-liposomal CV% of AUC for each
pair was 2.7 (P<0.001) (Eq 1). The mean ± SD ratio of AUCmax to AUCmin was 34.1 ± 41.9
for liposomes and 3.6 ± 1.8 for non-liposomal drugs. The ratio of liposomal to non-
liposomal ratio of AUCmax to AUCmin for each pair was 16.7 (P=0.13) (Eq 2).
Influence of Drug Clearance on Interpatient PK Variability
Given the high interpatient variability in the pharmacokinetic disposition and the slower
clearance rates often observed with liposomal anticancer agents, we evaluated the
relationship between total body clearance and CV% of AUC for liposomal and non-
liposomal formulations of the same anticancer agents. Graphical representations of the
relationship between clearance (CL) and PK variability for liposomal and non-liposomal
formulations are depicted in Figure 3A and Figure 3B, respectively. There was an inverse
relationship between the CL and PK variability of liposomal agents where liposomal agents
with a lower CL have a greater degree of PK variability (Figure 3A). For small molecule
agents, there was no relationship between CL and PK variability (Figure 3B).
Impact of Sampling Schema on Reported Interpatient PK Variability
To investigate how study design and sampling schema affects the estimated PK variability,
CV% of AUC and ratio of AUCmax to AUCmin were estimated using short (0–24 h) and
long (0–336 h) sampling model for patients at each dose level of S-CKD602 and NL-
CKD602. A complete list of reported CV% of AUC values and ratio of AUCmax to AUCmin
for 0 to 24 h and 0 to 336 h sampling, along with corresponding ratios are listed in Table 3
and Table 4, respectively. Matching values for NL-CKD602, obtained in the meta-analysis
section, are also listed here. A corresponding graphical representation is depicted in Figure
4A and Figure 4B. The estimated PK variability of S-CKD602 using concentration versus
time data from 0 to 366 h was greater at all doses compared with data from 0 to 24 h. At the
maximum tolerated dose of 2.1 mg/m2, there was a significant difference between AUC0–24
(19,121 ± 9,498 ng/mL·h) and AUC0–336 (52,390 ± 38,007 ng/mL·h) (P=0.037). Also at 2.1
mg/m2, the CV% of AUC0–24 and the CV% of AUC0–336 were 63.6 and 86.1, respectively.
The ratio of CV% of AUC0–336 to CV% of AUC0–24 was 1.4 (Eq 3). At this same dose, the
ratio of AUCmax to AUCmin was 4.9 when sampled from 0 h to 24 h and 12.1 when sampled
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from 0 h to 336 h. The ratio ofAUCmax to AUCmin of long schema to short schema was 2.5
(Eq 4).
Discussion
High inter-patient PK variability observed with many anticancer agents makes it difficult to
predict a patient’s response to a particular drug. Moreover, liposomes often report higher PK
variability compared with small molecules and non-liposomal agents, further clouding
predictions of outcomes associated with these carrier agents. We comprehensively evaluated
these differences in a meta-analysis of 9 liposomal and non-liposomal anticancer agents.
This is the first meta-analysis evaluating the PK variability of liposomal versus non-
liposomal agents. The results of our study show that there is significantly higher interpatient
PK variability of liposomal agents compared with non-liposomal agents. We also report that
liposomal agents with lower CL have a higher degree of PK variability. In addition, we
evaluated the impact a study’s design and sampling schema may have on reported inter-
patient PK variability in liposomes. There was higher reported AUC variability when
samples were obtained up to 14 days compared with 24 h. Thus, limiting sample collection
to 24 h after administration of a liposomal agent underestimates inter-patient PK variability.
Compared to non-liposomal anticancer agents, overall PK variability was demonstrated to
be greater for liposomes. First, variability in S-CKD602 was 9.8-fold higher than that of NL-
SCK602 when measured by the ratio of AUC ranges. Moreover, the meta-analysis provided
a broad assessment of PK variability differences between liposomal versus non-liposomal
forms of the same drug. Using a comprehensive list of liposomal anticancer agents that were
FDA approved or in clinical development, the PK variability of all liposomal agents were
significantly greater than non-liposomal small molecules (P<0.001). When measured by CV
%, the inter-patient PK variability associated with liposomal agents is 2.7-fold higher than
that of conventional formulations.
While the PK variability of liposomal agents was shown to be 17.3-fold higher when
measured by AUC range, this result was non-significant (P = 0.13). This can be attributed to
the small amount of reported AUC range data that was available, which lower our statistical
power. However, when evaluating the mean +/− SD CV% of AUC the PK variability
between liposomal and SM is statistically significant (P < 0.001). This issue high lights the
need for additional analyses and need for complete PK data (mean +/− SD, range) to be
published in all PK studies of liposomal and SM agents in order to provide an accurate
representation of the complete PK variability.
In addition to increased overall PK variability in S-CKD602 compared to NL-CKD602, we
also observed dose-dependent changes in PK variability with the liposomal formulation. The
trend of high PK variability at lower doses compared with higher doses of a liposomal agent
suggests the factors affecting the PK variability become more uniform at higher doses. One
potential mechanism for the reduced PK variability at higher doses is a saturation of
liposomal CL mediated by the MPS. This is further supported through analysis of AUC
variability of NL-CKD602, which was much more constant at low and high doses.
Saturation of NL-CKD602 clearance would not be expected to occur through the same
mechanism as liposomal agents as non-liposomal drugs are not thought to be cleared via the
MPS.
Our results showing an inverse relationship between the CL of liposomal agents and the
degree of interpatient PK variability has interesting ramifications for the design and
development of liposomal and nanoparticle agents. Liposomal agents with a lower CL have
a greater degree of PK variability (Figure 3A). This data suggests that liposomal agents with
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a lower CL is due to a slower and more variable recognition and uptake of the liposomal
agent by the MPS which leads to the higher PK variability. Consistent with this theory is
that for small molecule agents, there was no relationship between CL and PK variability as
these agents are not cleared by the MPS (Figure 3B). Thus, while engineering liposomal,
nanoparticle, and conjugated agents to achieve a slower CL and prolonged circulation time
in plasma to achieve higher exposures of drug delivered to target tissues (e.g. tumor), this
may introduce more PK and PD (toxicity and response) variability.
While liposomal anticancer agents often have high inter-patient variability in PK
parameters, levels of reported PK variability can also vary greatly between independent
studies of the same or similar liposomal technology. Reasons for this are multifactorial, with
plausible explanations being attributed to different patient demographics and disease states
represented in each study. However, differences in experimental design and sampling
schema between studies may also play a role by altering documentation of PK variability. In
a PK study of liposomal cisplatin (SPI-077) by Terwogt and colleagues, the calculated AUC
from 0 to 7 days following a dose of SPI-77 at 200 mg/m2 IV x 1was 71.1 ± 2.5 h·mM (CV
% = 3.5; n=3) [29]. In a different study performed by White et al., the reported SPI-077
AUC at this same dose determined from samples collected out to 22 days after
administration was 101.6 ± 31.7 h·mM (CV% = 31.2; n=12) [30]. Inspection of AUC CV%
values reveals that variability in SPI-077 exposure was reported to be 8.9-fold higher with
the extended sampling schema compared to a shorter collection model. These findings are
consistent with our analysis of S-CKD602, which showed that collecting PK samples out to
14 days resulted in as high as 2.5-fold higher reported PK variability than would be
documented if a shorter sampling model (0 to 24 h) were used in the same patients. Thus,
when plasma drug levels beyond 24 h were not included in AUC calculations, variability in
patient PK parameters was significantly underestimated. While this is not a concern for
conventional anticancer drugs, many of which are mostly cleared from the body after 24 h,
liposomal agents, such as S-CKD602 and PEGylated liposomal doxorubicin (Doxil), are
retained in circulation for much longer time periods (e.g. 7 to 28 days). Consequently,
sample collection must be extended to later time points when studying liposomes to ensure
accurate characterization of PK parameters of these agents.
It is important to note; however, that reported liposomal PK variability is not always larger
when an extended sampling model is utilized. In an example of two independent studies of
Doxil, PK variability following a dose of 40 mg/m2 IV x 1 was reported to be 1.5 fold
higher when sampled from baseline to 4 days (CV% 35.4; n=3) [31] than when sampled
from baseline to 7 days (CV% 23.1; n=4) [32]. While this data does not directly follow our
hypothesis, it is significant by revealing differences in variability that may be incorrectly
documented with an inadequate study designs. These findings further support the necessity
of employing a study design that allows adequate sample collection to ensure accurate
characterization of a liposomal agent’s PK disposition. This necessity also holds true for any
other nanoparticle, monoclonal antibody, or antibody-drug conjugate with a long half-life.
There are a multitude of properties that make carrier-mediated and liposomal agents unique
from the active small molecule drug that is contained within the nano-carrier. These
differences lead to significant variability in the pharmacokinetics and pharmacodynamics of
the carrier mediated drugs. It has been shown that physical properties of the carrier, the
MPS, presence of tumors in the liver, enhanced permeability and retention effect, drug-drug
interactions, age, and gender all contribute in varying degrees to the pharmacokinetic
disposition and pharmacodynamic endpoints of carrier mediated agents in patients [45,46.
Due to the unique and highly variable clearance mechanisms of liposomes, it is important to
continue to extensively evaluate them during all phases of preclinical and clinical
development. Areas of research that can aid in our understanding of how these agents are
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handled and how we may predict their actions in patients, include: pharmacogenomics,
cellular function (probing the MPS), more sensitive and accurate analytical PK methods, and
identification of the optimal preclinical (animal and in vitro) models [48–50].
In conclusion, this is the first study that systematically reporting greater inter-patient PK
variability of liposomal agents compared with non-liposomal agents and the impact that a
study’s sampling schema has on reported PK variability. Our results also have interesting
ramifications for the design and development of liposomal and nanoparticle agents.
Development of a standardized sampling strategy that may be applied to all liposomal agents
and potentially all nanoparticle and conjugated agents is warranted as a means of reducing
inaccurate documentation of PK variability that arises from suboptimal study designs.
Future studies must also further evaluate the sources of PK variability and develop
additional tools to accurately measure and predict PK and PD variability in patients
administered liposomal, nanoparticle and conjugated agents.
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Representative plasma concentration-vs.-time profiles of encapsulated S-CDK602 at 2.1 mg/
m2 IV x 1 and NL-CKD602 at 0.5 mg/m2 IV x 1. Doses represent the MTD of each
respective agent.
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Figure 2A. Reported inter-individual PK variability for 9 anticancer agents as measured by
CV% of AUC. Black bars represent liposomal formulations of each agent. Dotted gray bars
represent corresponding non-liposomal formulations at similar doses.
Figure 2B. Comprehensive inter-individual PK variability for liposomal and non-liposomal
anticancer agents. Black bars represent liposomal formulations of each agent. Dotted gray
bars represent corresponding non-liposomal formulations at similar doses.
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Figure 3A. The relationship between total body clearance and PK variability of each
liposomal agent evaluated in the meta-analysis. Each agent is evaluated at its respective
MTD determined in published PK studies
Figure 3B. The relationship between total body clearance and PK variability of each non-
liposomal agent evaluated in the meta-analysis. Each agent is evaluated at available doses
that corresponded most closely to the liposomal MTD determined in published PK studies
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Figure 4A. Reported variability of S-CKD602 AUC measured for 0–336h and 0–24h, as
well as NL-CKD602 at 0 - ∞. PK variability is depicted as comparisons of CV% of AUC
values at each dose.
Figure 4B. Reported variability of S-CKD602 AUC measured from 0–336h and 0–24h, as
well as NL-CKD602 at 0 - ∞. PK variability is depicted as comparisons of ratio of AUCmax
to AUCmin values at each dose.
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